Press release
COPD Drug Market to Rise at an Estimated Value of USD 69.29 billion by 2026, Report by AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Chiesi Farmaceutici S.p.A and others
The Global Burden of Disease Study reports a prevalence of 251.00 million cases of chronic obstructive pulmonary disease (COPD) globally in 2016. Globally, it is estimated that 3.17 million deaths were caused by the disease in 2015 (that is, 5% of all deaths globally in that year)
Download Sample PDF Report https://databridgemarketresearch.com/request-a-sample/?dbmr=global-chronic-obstructive-pulmonary-disease-copd-drug-market
Global chronic obstructive pulmonary disease drug market is rising gradually to an estimated value of USD 69.29 billion by 2026 registering a steady CAGR of 4.3% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients, growing prevalence of chronic obstructive pulmonary disease (COPD) associated diseases and rising patient population and increase in availability of novel combination therapy drugs.
Key Market Players: Global COPD Drug Market
Few of the major competitors currently working in the chronic obstructive pulmonary disease (COPD) drug market are
• AstraZeneca
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Novartis AG
• Chiesi Farmaceutici S.p.A
• Sunovion Pharmaceuticals Inc
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Orion Corporation
• Merck & Co., Inc
• Abbott
• F. Hoffmann-La Roche Ltd
• Vectura Group plc
• Pfizer Inc
• Alkermes
• Mylan N.V
• Almirall
• S.A, Genentech, Inc
• Biogen
• Vectura Group plc and few among others
Key Developments in the Market:
• In April 2019, Circassia and AstraZeneca received collaborative FDA approval for Duaklir which is a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and long-acting beta-agonist (LABA) formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease (COPD), administered twice-daily via the AstraZeneca’s breath-actuated inhaler Pressair
• In February 2019, Mylan N.V received FDA approval for Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) which is first generic version of Advair Diskus by GlaxoSmithKline Plc. This drug is used for the treatment of asthma or other chronic obstructive pulmonary disease (COPD). As it is a first substitutable generic of ADVAIR DISKUS it increases affordability to all healthcare system
Get Detailed TOC https://databridgemarketresearch.com/toc/?dbmr=global-chronic-obstructive-pulmonary-disease-copd-drug-market
Segmentation: Global Chronic Obstructive Pulmonary Disease (COPD) Drug Market
By Type
• Chronic bronchitis
• Pulmonary emphysema
• Asthma
By Mechanism Type
• Bronchodilators
• Selective β2-adrenergic agonists (short- and long-acting)
• Theophylline
• Anticholinergics
• Glucocorticoids
• Anti-muscarinic drugs
By Drug Type
• Aclidinium
• Arformoterol
• Formoterol
• Glycopyrrolate
• Indacaterol
• albuterol
• Levalbuterol
• Prednisolone
• Fluticasone
By Therapy
• Oxygen therapy
• Pulmonary Rehabilitation Program
By Route of Administration
• Oral
• Inhaled
• Intravenous
• Others
By Device Type
• Inhalers
• Pressurized metered-dose inhalers (MDIS)
• Dry-powder inhalers (DPIS)
• Nebulizers
• Soft mist inhalers
• Others
By End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
By Geography
• North America
• South America
• Europe
• Asia-Pacific
• Middle East & Africa
Global chronic obstructive pulmonary disease (COPD) drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of chronic obstructive pulmonary disease drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Speak to Author https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-chronic-obstructive-pulmonary-disease-copd-drug-market
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release COPD Drug Market to Rise at an Estimated Value of USD 69.29 billion by 2026, Report by AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Chiesi Farmaceutici S.p.A and others here
News-ID: 1794172 • Views: …
More Releases from Data Bridge Market Research
Precision gearbox market grow at a CAGR of 9.1% in the forecast period of 2022 t …
Precision gearbox market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to reach at an estimated value of USD 5.9 billion by 2029 and grow at a CAGR of 9.1% in the above-mentioned forecast period.
Market Overview
This precision gearbox market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market…
Neuropathic Pain Market is expected to undergo a CAGR of 9.2% during the forecas …
Data Bridge Market Research analyses that the global neuropathic pain market, which was USD 5.86 billion in 2023, is expected to reach USD 11.86 billion by 2031, and is expected to undergo a CAGR of 9.2% during the forecast period of 2024 to 2031.
Market Overview
Neuropathic pain is a type of chronic pain caused by damage or dysfunction of the nervous system. It often presents as burning, shooting, or electric shock-kind…
Radiology market registering a CAGR of 6.20% during the forecast period of 2022- …
Radiology market was valued at USD 26.6 billion in 2021 and is expected to reach USD 43.04 billion by 2029, registering a CAGR of 6.20% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Overview
Radiology (also referred as diagnostic imaging) includes multiple tests are included in the process, which…
Cervical Retractors Market Size, Share, Trends, Key Drivers, Growth and Opportun …
Global Cervical Retractors Market report focuses on several essential parameters related to the market that includes but are not limited to a competitive landscape, brief segmentation and industrial infrastructure. This marketing report offers an in-depth overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. Cervical Retractors market is supposed to grow during the forecast period due to growing demand…
More Releases for COPD
Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing…
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's.
It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be…
COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858
The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market…
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would…
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the…
Asthma and COPD Drugs Market: High Costs of Asthma and COPD Drugs and Consumer A …
Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the…
